查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1591875

医院感染治疗药物市场：依药物类型、感染疾病- 全球预测 2025-2030

Hospital Infection Therapeutics Market by Drug Type (Antibacterial Drugs, Antifungal Drugs, Antiviral Drugs), Infections (Bloodstream Infections, Gastrointestinal Disorders, Hospital-Acquired Pneumonia) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年医院感染治疗药物市场规模为59亿美元，预计2024年将达63.8亿美元，复合年增长率为8.27%，2030年将达到102.9亿美元。

医院感染治疗药物市场是医疗保健行业的一个专门部门，专注于医院环境中发生的感染疾病的治疗和管理。这些感染疾病通常称为医院感染或医疗保健相关感染 (HAIs)，包括 MRSA、艰难梭菌和血流感染等疾病。 HAI 会导致住院时间延长、医疗费用增加和死亡率增加，从而增加了对此类治疗的需求。医院感染治疗药物包括抗生素、抗病毒药物和抗真菌药物，主要由专门从事感染疾病的临床医生在医院环境中使用。最终用途包括医院、诊所和专门的感染疾病治疗中心。影响该市场的关键成长要素包括老年人口的增加、外科手术数量的增加以及导致早期检测的诊断工具的进步。此外，政府旨在预防和控制感染的措施正在创造市场扩张的潜力。生物技术的最新创新和人工智慧在药物发现中的出现提供了充满希望的机会。然而，市场成长面临抗生素抗药性和严格的监管核准等挑战，这可能会减缓产品的推出和创新。该市场的创新可能集中在开发新的抗菌药物、噬菌体疗法等替代疗法以及提高治疗效果的快速诊断测试。製药公司与研究机构之间的策略联盟有助于克服研发成本高等限制。透过投资研发，特别是针对患者独特感染情况量身定制的个人化医疗方法，可以实现业务成长。此外，可以利用巨量资料分析来深入了解感染模式并优化治疗性介入。市场竞争激烈，并受到对治疗的持续需求的推动，需要灵活的创新来应对新出现的传染病挑战和监管发展。

主要市场统计
基准年[2023] 59亿美元
预测年份 [2024] 63.8亿美元
预测年份 [2030] 102.9亿美元
复合年增长率（%） 8.27%

市场动态：快速发展的医院感染治疗市场的关键市场洞察

供需的动态交互作用正在改变医院感染药物市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 慢性病增加导致老年人口增加
    • 迅速重视感染控制政策
    • 完善报销政策
  • 市场限制因素
    • 对产品召回的担忧
  • 市场机会
    • 加大医院感染治疗药物研发投入
    • 政府对药品/药物的有利核准
  • 市场挑战
    • 关于医院感染的严格监管要求

波特五力：驾驭医院感染药物市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解医院感染治疗药物市场的外部影响

外部宏观环境因素在塑造医院感染治疗药物市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解医院感染治疗药物市场的竞争状况

医院感染治疗药物市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 医院感染治疗药物市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估医院感染治疗药物市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析与建议，规划医院感染治疗药物市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，对医院感染治疗药物市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病增加导致老年人口增加
      • 对感染控制政策的重视正在迅速增加
      • 改进退款政策
    • 抑制因素
      • 对产品召回的担忧
    • 机会
      • 加大医院感染治疗药物研发投入
      • 政府核准药品
    • 任务
      • 严格医院感染监管要求
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章依药品类型分類的医院感染治疗药品市场

  • 抗生素
  • 抗真菌药物
  • 抗病毒药物

第七章感染疾病医院感染治疗药品市场

  • 血流感染疾病
  • 胃肠道疾病
  • 院内肺炎
  • 手术部位感染
  • 尿道感染

第八章北美和南美医院感染治疗药物市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第九章亚太医院感染治疗药物市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十章欧洲、中东和非洲医院感染治疗药物市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十一章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca PLC
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol Myers Squibb Company
  • Daiichi Sankyo Company, Limited
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences Inc.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Sanofi SA
  • Spero Therapeutics
Product Code: MRR-43127F7278A5

The Hospital Infection Therapeutics Market was valued at USD 5.90 billion in 2023, expected to reach USD 6.38 billion in 2024, and is projected to grow at a CAGR of 8.27%, to USD 10.29 billion by 2030.

The Hospital Infection Therapeutics market is a specialized segment of the healthcare industry focused on the treatment and management of infections acquired in hospital settings. These infections, often termed nosocomial or healthcare-associated infections (HAIs), include conditions such as MRSA, C. difficile, and bloodstream infections. The necessity for such therapeutics has risen due to the increasing incidence of HAIs, which contribute to prolonged hospital stays, higher healthcare costs, and significant mortality rates. The application of hospital infection therapeutics spans antibiotics, antiviral, and antifungal agents, used primarily in hospital environments by clinicians specializing in infectious diseases. End-use sectors include hospitals, clinics, and specialized infection treatment centers. Key growth factors influencing this market include the growing geriatric population, increasing surgical procedures, and advancements in diagnostic tools leading to early detection. Moreover, government initiatives aimed at infection prevention and control create potential for market expansion. Recent biotechnology innovations and the advent of AI in drug discovery present promising opportunities. However, market growth faces challenges such as antibiotic resistance and stringent regulatory approvals, which can delay product launches and innovation. Innovations in this market are likely to focus on developing new antimicrobial agents, alternative therapies like phage therapy, and rapid diagnostic tests that enhance treatment efficacy. Strategic collaborations among pharmaceutical companies and research institutions can help overcome limitations such as high R&D costs. Business growth is feasible through investments in R&D, especially in personalized medicine approaches tailored to patient-specific infection profiles. Additionally, leveraging big data analytics can provide insights into infection patterns, optimizing therapeutic interventions. The market is competitive, driven by continuous need for improved therapeutics, and necessitates agile innovation to address emerging infection challenges and regulatory landscapes.

KEY MARKET STATISTICS
Base Year [2023] USD 5.90 billion
Estimated Year [2024] USD 6.38 billion
Forecast Year [2030] USD 10.29 billion
CAGR (%) 8.27%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Hospital Infection Therapeutics Market

The Hospital Infection Therapeutics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Growing geriatric population with the increase in the number of chronic diseases
    • Rapidly growing emphasis on infection control policies
    • Improvements in reimbursement policies
  • Market Restraints
    • Concerns related to product recalls
  • Market Opportunities
    • Increasing investments in R&D on hospital infection therapeutics
    • Favorable drug and medication approvals by government
  • Market Challenges
    • Stringent Regulatory Requirements for Hospital Acquired Infection

Porter's Five Forces: A Strategic Tool for Navigating the Hospital Infection Therapeutics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Hospital Infection Therapeutics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Hospital Infection Therapeutics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Hospital Infection Therapeutics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Hospital Infection Therapeutics Market

A detailed market share analysis in the Hospital Infection Therapeutics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Hospital Infection Therapeutics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Hospital Infection Therapeutics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Hospital Infection Therapeutics Market

A strategic analysis of the Hospital Infection Therapeutics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Hospital Infection Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., AstraZeneca PLC, Basilea Pharmaceutica Ltd., Bayer AG, Bristol Myers Squibb Company, Daiichi Sankyo Company, Limited, F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline PLC, Johnson & Johnson Services Inc., Merck & Co., Inc., Pfizer Inc., Sanofi S.A., and Spero Therapeutics.

Market Segmentation & Coverage

This research report categorizes the Hospital Infection Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Antibacterial Drugs, Antifungal Drugs, and Antiviral Drugs.
  • Based on Infections, market is studied across Bloodstream Infections, Gastrointestinal Disorders, Hospital-Acquired Pneumonia, Surgical Site Infections, and Urinary Tract Infection.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing geriatric population with the increase in the number of chronic diseases
      • 5.1.1.2. Rapidly growing emphasis on infection control policies
      • 5.1.1.3. Improvements in reimbursement policies
    • 5.1.2. Restraints
      • 5.1.2.1. Concerns related to product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing investments in R&D on hospital infection therapeutics
      • 5.1.3.2. Favorable drug and medication approvals by government
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent Regulatory Requirements for Hospital Acquired Infection
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Hospital Infection Therapeutics Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Antibacterial Drugs
  • 6.3. Antifungal Drugs
  • 6.4. Antiviral Drugs

7. Hospital Infection Therapeutics Market, by Infections

  • 7.1. Introduction
  • 7.2. Bloodstream Infections
  • 7.3. Gastrointestinal Disorders
  • 7.4. Hospital-Acquired Pneumonia
  • 7.5. Surgical Site Infections
  • 7.6. Urinary Tract Infection

8. Americas Hospital Infection Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Hospital Infection Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Hospital Infection Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. AstraZeneca PLC
  • 4. Basilea Pharmaceutica Ltd.
  • 5. Bayer AG
  • 6. Bristol Myers Squibb Company
  • 7. Daiichi Sankyo Company, Limited
  • 8. F. Hoffmann-La Roche Ltd.
  • 9. Gilead Sciences Inc.
  • 10. GlaxoSmithKline PLC
  • 11. Johnson & Johnson Services Inc.
  • 12. Merck & Co., Inc.
  • 13. Pfizer Inc.
  • 14. Sanofi S.A.
  • 15. Spero Therapeutics

LIST OF FIGURES

  • FIGURE 1. HOSPITAL INFECTION THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. HOSPITAL INFECTION THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. HOSPITAL INFECTION THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIBACTERIAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIFUNGAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY ANTIVIRAL DRUGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY BLOODSTREAM INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY GASTROINTESTINAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY HOSPITAL-ACQUIRED PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY SURGICAL SITE INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY URINARY TRACT INFECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 19. AMERICAS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 24. CANADA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 26. MEXICO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. MEXICO HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 28. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 30. UNITED STATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 31. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 33. ASIA-PACIFIC HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 34. AUSTRALIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AUSTRALIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 36. CHINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. CHINA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 38. INDIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. INDIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 40. INDONESIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. INDONESIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 42. JAPAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. JAPAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 44. MALAYSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. MALAYSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 46. PHILIPPINES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. PHILIPPINES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 48. SINGAPORE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. SINGAPORE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 50. SOUTH KOREA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. SOUTH KOREA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 52. TAIWAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. TAIWAN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 54. THAILAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. THAILAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 56. VIETNAM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. VIETNAM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 58. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 60. EUROPE, MIDDLE EAST & AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 61. DENMARK HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. DENMARK HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 63. EGYPT HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. EGYPT HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 65. FINLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. FINLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 67. FRANCE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. FRANCE HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 69. GERMANY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. GERMANY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 71. ISRAEL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. ISRAEL HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 73. ITALY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. ITALY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 75. NETHERLANDS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NETHERLANDS HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 77. NIGERIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. NIGERIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 79. NORWAY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. NORWAY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 81. POLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. POLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 83. QATAR HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. QATAR HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 85. RUSSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. RUSSIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 87. SAUDI ARABIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SAUDI ARABIA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SOUTH AFRICA HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 91. SPAIN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SPAIN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 93. SWEDEN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. SWEDEN HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 95. SWITZERLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. SWITZERLAND HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 97. TURKEY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. TURKEY HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 99. UNITED ARAB EMIRATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. UNITED ARAB EMIRATES HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 101. UNITED KINGDOM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. UNITED KINGDOM HOSPITAL INFECTION THERAPEUTICS MARKET SIZE, BY INFECTIONS, 2018-2030 (USD MILLION)
  • TABLE 103. HOSPITAL INFECTION THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 104. HOSPITAL INFECTION THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023